Why the study?
Current HFrEF therapies do not address symptoms stemming from reduced cardiac output and reserve, and definitive clinical trials of positive inotropes have failed to demonstrate a survival benefit.
Design
State-of-the-art review
Authors
Loading...
Reinforces caution against positive inotropes for survival in chronic HF; leaves open refined trials with better selection and functional endpoints.
Despite past failures of positive inotropes to improve survival in HFrEF, this review proposes a new framework for future trials focusing on patient selection, biomarkers, and functional outcomes.
Ahmad et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: